SCHEMBL2588020

SCHEMBL2588020

Fc1ccc(-c2c(P(=S)(c3ccccc3)c3ccccc3)n3ccccc3[n+]2CC=Cc2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 17/20 0.42
CHRM2 P08172 3/20 0.36
CHRM4 P08173 3/20 0.36
CHRM5 P08912 3/20 0.36
ADRA2A P08913 3/20 0.36
CHRM1 P11229 3/20 0.36
ADRA2C P18825 3/20 0.36
CHRM3 P20309 3/20 0.36
SLC6A2 P23975 3/20 0.36
HTR2A P28223 3/20 0.36
OPRM1 P35372 3/20 0.36
SIGMAR1 Q99720 3/20 0.36
ADRB3 P13945 2/20 0.36
S1PR1 P21453 2/20 0.36
FPR1 P21462 2/20 0.36
HRH2 P25021 2/20 0.36
FPR3 P25089 2/20 0.36
AGTR1 P30556 2/20 0.36
GPR183 P32249 2/20 0.36
APLNR P35414 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2586255 0.80 NPSR1 (0.45) NPSR1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL2593678 0.70 NPSR1 (0.51) NPSR1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL31086739 0.67 LMNA (0.33) NPSR1NFE2L2MEN1KMT2ALMNA
SCHEMBL31086927 0.64 ALDH1A1 (0.37) NPSR1HTR2ASIGMAR1CYP2D6MEN1
SCHEMBL31086888 0.62 HTT (0.33) MEN1KMT2ALMNAMAPT
SCHEMBL31086971 0.62 HTT (0.33) MEN1KMT2ALMNAMAPT
SCHEMBL2593549 0.62 NPSR1 (0.58) NPSR1KMT2AMAPT
SCHEMBL31086669 0.61 PAM (0.34) NPSR1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL2594217 0.60 NPSR1 (0.45) NPSR1MEN1KMT2A
SCHEMBL31086899 0.59 MAPT (0.39) NPSR1CYP2D6MEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011137220-A1 SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-11-03 WO disclosed